Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer-Reference-Cited by-同舟云学术

Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer

Published:2024-06-14 Issue:8 Volume:24 Page:717-729
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Pacholczak-Madej Renata¹²³^ORCID,Bartoletti Michele⁴,Musacchio Lucia⁵,Püsküllüoglu Mirosława⁶,Blecharz Paweł¹,Lorusso Domenica¹⁷

Affiliation:

1. Department of Gynaecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Krakow, Poland

2. Department of Chemotherapy, The District Hospital, Sucha Beskidzka, Poland

3. Department of Anatomy, Jagiellonian University, Krakow, Poland

4. Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy

5. Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

6. Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Krakow, Poland

7. Gynecologic Oncology Unit, Humanitas San Pio X Milan and Humanitas University Rozzano, Milan, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2024.2367472

Reference66 articles.

1. Differential trends in rising endometrial cancer incidence by age, race, and ethnicity

2. Risk factors for endometrial cancer: An umbrella review of the literature

3. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis

4. Management of Endometrial Cancer: Molecular Identikit and Tailored Therapeutic Approach

5. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)